Patent · US Active

Immunogenic peptide against group a Streptococcus

US11732033B2 · kind B2 · utility

0Cited by

0References

17Claims

0Family size

Assignee

GRIFFITH UNIVERSITY · AU

Inventors

Michael Good · Forsayth, AU
Manisha Pandey · Forsayth, AU
Michael Batzloff · Calle de la Era, AU

Key dates

Filing date	Aug 22, 2018
Grant date	Aug 22, 2023
Priority date	—
Expiry date	Jun 3, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K14/315
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A Streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 5 peptide may be particularly efficacious. An S2 peptide or variant may be co-administered with the modified p145 peptide to enhance the immune response.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.